Physician profile
Sanjiv Kumar
NPI 1639286719
$4,169.31
in general payments reported to CMS, 2019-2025
20 companies · $690 in 2025
The $690 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,368 · 2020: $339 · 2021: $112 · 2022: $576 · 2023: $465 · 2024: $618 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,029.28 | 2019 | |
| Biotissue Holdings INC. | $593.12 | 2023-2025 | |
| Alcon Vision LLC | $365.24 | 2019-2025 | Clareon, Hydrus Microstent |
| Merz North America, INC. | $352.68 | 2020-2022 | |
| Allergan, INC. | $329.12 | 2019-2022 | |
| Abbvie INC. | $170.38 | 2022 | |
| Sight Sciences, INC. | $136.96 | 2025 | Omni Surgical System |
| Mallinckrodt Hospital Products INC. | $130.81 | 2025 | Acthar |
| Astellas Pharma US INC | $127.12 | 2024 | Izervay |
| Genentech USA, INC. | $125.00 | 2022 | |
| Apellis Pharmaceuticals, INC. | $124.99 | 2023 | Syfovre |
| Dompe US, INC. | $121.85 | 2024 | Oxervate |
| Amgen INC. | $121.63 | 2024 | Tepezza |
| Ocular Therapeutix, INC. | $107.14 | 2022 | |
| Rxsight INC | $101.10 | 2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $98.24 | 2020 | |
| Bausch & Lomb Americas INC. | $60.26 | 2022-2023 | Vyzulta, Lotemax Sm, Prolensa |
| Galderma Laboratories, L.P. | $39.18 | 2020-2024 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Oyster Point Pharma, INC. | $15.81 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjiv Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.